Medannex is
developing antibodies
to target annexin-A1,
a protein that plays
a key role in the
immune system.

Medannex won an
innovation award at
Corporate LiveWire’s
Healthcare & Life
Sciences Awards 2018,
in recognition of
the huge potential
of our innovative approach.


 

Our antibodies specifically target and inhibit annexin-A1, a protein that modulates the immune system and plays a key role in the development of many cancers and autoimmune conditions.

We are collaborating with both Dr Stefan Symeonides at the Edinburgh Cancer Research Centre and an NHS NIHR Lupus Centre of Excellence to ensure that we realise the full potential of our novel therapeutic approach.

Medannex recently presented pre-clinical data at a Nature Reviews Cancer conference showing the ability of our antibody MDX-124 to reduce cancer cell growth by up to 76%, and also to markedly reduce tumour volume.

Our technology is protected by a robust intellectual property portfolio which includes patents granted in all major territories. Feedback from leading clinicians and global pharma companies has confirmed that annexin-A1 is a unique target with major therapeutic potential in both oncology and autoimmune diseases.

 


Collaborations & Affiliations

Medannex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.